Linvoseltamab is a BCMAxCD3 bispecific antibody in development for the treatment of relapsed/refractory multiple myeloma.
Multiple myeloma is a blood cancer characterized by the proliferation of cancerous plasma cells (multiple myeloma cells) that crowd out healthy blood cells in the bone marrow, infiltrate other tissues and cause potentially life-threatening organ injury.
Linvoseltamab is an investigational treatment designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing.
A Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy has been accepted for review by the U.S. Food and Drug Administration (FDA). The target action date for the FDA decision is July 10, 2025.
